Dr Petrylak speaks with ecancertv at the Best of ASCO 2016 about novel therapies to treat prostate and bladder cancers.

In prostate cancer, he describes studies which find lower doses of docetaxel are equivalent in overall survival to higher doses of cabazitaxel.

Dr Petrylak also considers immunotherapy developments against bladder cancer, including checkpoint inhibitors and two new monoclonal antibodies.

For more on atezolizumab to treat bladder cancer, we spoke to Dr Arjun Balar.

Also available is our expert review of advances in prostate cancer from ASCO 2016.